Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

LGND

L

Ligand Pharmaceuticals Incorporated (LGND)

NGM – Цена в реальном времени. Валюта: USD

303.59

+7.67 (2.59%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

303.00

-0.59 (-0.19%)

После закрытия: Jun 26, 2026, 5:54 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.

Ligand Announces 2026 Investor Day in New York City

Ligand Announces 2026 Investor Day in New York City

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m.

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Common Stock holdings, reducing direct ownership to 41,382 shares post-transaction.

Ligand to Participate in June Investor Conferences

Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference.

Saying Goodbye To The XOMA Royalty PFDs

Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

Видео

No Data

There is no data to display

Пресс-релизы

Ligand Announces 2026 Investor Day in New York City

Ligand Announces 2026 Investor Day in New York City

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m.

Ligand Reports First Quarter 2026 Financial Results

07.05.2026

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold.